Cargando…

Differential clinical profile of candesartan compared to other angiotensin receptor blockers

The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers rep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cernes, Relu, Mashavi, Margarita, Zimlichman, Reuven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253768/ https://www.ncbi.nlm.nih.gov/pubmed/22241949 http://dx.doi.org/10.2147/VHRM.S22591

Ejemplares similares

Effects of candesartan, an angiotensin II receptor type I blocker, on atrial remodeling in spontaneously hypertensive rats
por: Choisy, Stéphanie C., et al.
Publicado: (2015)

No effect of the angiotensin receptor blocker candesartan on cerebrovascular autoregulation in rats during very high and low sodium intake
por: Sigurdsson, Sigurdur T, et al.
Publicado: (2019)

Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation
por: Lee, Jin Wook, et al.
Publicado: (2023)

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke
por: Kikuchi, Kiyoshi, et al.
Publicado: (2013)

Transcriptomic Analysis of Mouse Brain After Traumatic Brain Injury Reveals That the Angiotensin Receptor Blocker Candesartan Acts Through Novel Pathways
por: Attilio, Peter J., et al.
Publicado: (2021)

Comparative assessment of angiotensin receptor blockers in different clinical settings
por: Verdecchia, Paolo, et al.
Publicado: (2009)

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
por: Blankestijn, P. J, et al.
Publicado: (2008)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Angiotensin receptor blocker neprilysin inhibitors
por: Usuda, Daisuke, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer
por: Tabatabai, Ehsan, et al.
Publicado: (2021)

Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity
por: Lin, Wen-Yu, et al.
Publicado: (2022)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

COVID-19, Angiotensin Receptor Blockers, and the Brain
por: Saavedra, Juan M.
Publicado: (2020)

The use of angiotensin receptor blockers in dementia prevention
por: Müller, Jordana de Araujo, et al.
Publicado: (2023)

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man
por: Alessandra, Del Fiorentino, et al.
Publicado: (2009)

Challenges in Comparing Effectiveness of Angiotensin Receptor Blockers vs. Angiotensin-Converting Enzyme Inhibitors for Hypertension in Medicare Data
por: Setoguchi, Soko, et al.
Publicado: (2011)

A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers
por: Sadjadi, Seyed Ali, et al.
Publicado: (2009)

Comparative Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Coronary Artery Bypass Grafting
por: Kim, Jeayoun, et al.
Publicado: (2020)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Angiotensin II receptor type 1 blocker candesartan improves morphine tolerance by reducing morphine-induced inflammatory response and cellular activation of BV2 cells via the PPARγ/AMPK signaling pathway
por: Zhao, Wenxin, et al.
Publicado: (2022)

Candesartan in heart failure
por: Ripley, Toni L, et al.
Publicado: (2006)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
por: Ram, C Venkata S
Publicado: (2011)

Angiotensin receptor blocker-induced bilateral ciliochoroidal effusion
por: Aggarwal, Kanika, et al.
Publicado: (2020)

Angiotensin Receptor Blockers Associated Enteropathy-Brief Report
por: Gosai, Neha, et al.
Publicado: (2022)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

Potential use of angiotensin receptor blockers in skin pathologies
por: Hedayatyanfard, Keshvad, et al.
Publicado: (2023)

A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
por: Wang, Ji-Guang
Publicado: (2009)

Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction
por: Ko, Dennis, et al.
Publicado: (2019)

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
por: Nixon, R M, et al.
Publicado: (2009)

Angiotensin Receptor Blockers Upregulate Angiotensin Type 4 Receptor in Brains of Cognitively Intact Individuals
por: Cosarderelioglu, Caglar, et al.
Publicado: (2021)

Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis
por: Johansen, Thomas Lund, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_sgaf4d13pqmklbg97fociigoae